CAR based immunotherapy of solid tumours – a survey of the emerging targets.

John Maher, David Davies

Research output: Contribution to journalReview articlepeer-review

5 Citations (Scopus)


Immunotherapy with CAR T-cells has revolutionised the treatment of B-cell and plasma cell-derived cancers. However, solid tumours present a much greater challenge for treatment using CAR-engineered immune cells. In a partner review, we have surveyed data generated in clinical trials in which patients with solid tumours that expressed any of 30 discrete targets were treated with CAR-based immunotherapy. That exercise confirms that efficacy of this approach falls well behind that seen in haematological malignancies, while significant toxic events have also been reported.
Here, we consider approximately 60 additional candidates for which such clinical data are not available yet, but where pre-clinical data have provided support for their advancement to clinical evaluation as CAR target antigens.
Original languageEnglish
Article number1171
Pages (from-to)1171
Number of pages30
Issue number4
Publication statusPublished - 11 Feb 2023


  • solid tumour
  • chimeric antigen receptor
  • T-cell
  • NK cell
  • target
  • toxicity


Dive into the research topics of 'CAR based immunotherapy of solid tumours – a survey of the emerging targets.'. Together they form a unique fingerprint.

Cite this